New Pill Doubles Survival Time for Myeloma Patients
A breakthrough oral medication helped multiple myeloma patients live 18 months without their cancer worsening, more than double the time compared to standard treatment. The results offer fresh hope for thousands of people whose cancer has stopped responding to other therapies.